Search Results
Your search for Mindy Tanzola, PhD,Mindy Tanzola, PhD matches 9 pages
Showing 1 - 9ASCO Releases Resource-Stratified Guideline for the Treatment of Metastatic Breast Cancer
ASCO has released a new guideline on the treatment of patients with metastatic breast cancer in resource-constrained settings, where maximal setting–recommended treatments are not available.1 The guideline, designed for clinicians, policymakers, and patients, provides stratified recommendations...
ASCO Updates Guideline on Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer
Results from a series of randomized, controlled trials have prompted an update to the ASCO guideline on venous thromboembolism (VTE) prophylaxis and treatment in patients with cancer. The revised guideline, which had last been updated in 2019, is available from the Journal of Clinical Oncology.1...
ASCO Updates Guideline for Management of Anxiety and Depression in Adult Cancer Survivors
Cancer takes a significant psychological toll on affected individuals. Cancer survivors have a significantly elevated risk of developing a mental health disorder compared with the general population, yet their psychological symptoms are often underrecognized and undertreated. To help equip...
EAU and ASCO Release Collaborative Guidelines on Penile Cancer
Penile cancer is a rare disease with an incidence that is rising globally. Driven by a goal to offer clinicians and patients guidance on the management of this rare condition, ASCO collaborated with the European Association of Urology (EAU) to develop new guidelines on its diagnosis and treatment....
ASCO Updates Guideline on Sacituzumab Govitecan-hziy in Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer
ASCO has released a rapid recommendation update to the guideline on chemotherapy and targeted therapy for endocrine-pretreated or hormone receptor–negative metastatic breast cancer, addressing the use of sacituzumab govitecan-hziy in patients with endocrine-resistant, hormone receptor–positive,...
ASCO Publishes New Guideline on Immunotherapy, Biomarker Testing in Advanced Head and Neck Cancer
A new ASCO guideline is available on the use of immunotherapy and biomarker testing for patients with recurrent or metastatic head and neck squamous cell carcinoma. The guideline provides recommendations related to PD-L1 and tumor mutational burden (TMB) testing, selection of therapy in the...
ASCO Guideline Update for Systemic Melanoma Therapy Addresses New Treatment Option for Uveal Melanoma
A rapid update to the ASCO guideline on systemic therapy for melanoma adds a new recommendation for the treatment of patients with metastatic uveal melanoma.1 The update follows the January 2022 U.S. Food and Drug Administration (FDA) approval of tebentafusp-tebn for patients with previously...
ASCO Guideline Rapid Update Addresses the Use of Neoadjuvant Pembrolizumab in High-Risk Early-Stage Triple-Negative Breast Cancer
A rapid update to the ASCO Guideline on neoadjuvant therapy for breast cancer adds a recommendation on the use of pembrolizumab in patients with high-risk early-stage triple-negative breast cancer.1 The update follows a recent analysis from the randomized phase III KEYNOTE-522 trial that showed a...
ASCO Updates Guidance on Use of Abemaciclib and Endocrine Therapy in Patients With High-Risk Early Breast Cancer
A rapid update to the ASCO guideline on optimal adjuvant chemotherapy and targeted therapy for early breast cancer provides guidance on the use of the oral cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitor abemaciclib with endocrine therapy in patients with high-risk early breast cancer.1 The...
